Biosyent Inc (BIOYF) 8.6321 $BIOYF
BioSyent Pharma Launches New Proktis-M(R) Suppositories
Marketwired - Mon Nov 24, 7:07AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M(R) suppositories.
RX.VN: 10.250 (+0.010)
BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
Marketwired - Mon Oct 20, 7:06AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Third Quarter (Q3 2014) and nine months financial results for the three and nine months ending September 30, 2014. Key highlights include:
RX.VN: 10.250 (+0.010)
BioSyent Releases Q2 and Six Month Results-Q2 Sales Increase 72%, Net Income After Tax Up 112%
Marketwire - Thu Aug 21, 7:03AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Second Quarter (Q2 2014) and first half (H1 2014) financial results for the three and six months ending June 30, 2014. Key highlights include:
RX.VN: 10.250 (+0.010)
BioSyent Pharma Signs Exclusive Licensing and Distribution Agreement For New Urgent Care Drug Product
Marketwire - Wed Jul 23, 8:44AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and Distribution Agreement with an existing European partner for a new product that will be marketed by its' Hospital Products Division. The new product utilizes a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies. The product will be launched after Health Canada approval.
RX.VN: 10.250 (+0.010)
BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com
Thomson Reuters ONE - Mon Jul 07, 6:28PM CDT
Vancouver, BC, July 7, 2014 - Toronto based eResearch has issued a StockPotentials report on BioSyent Inc. (TSXV:RX), a Toronto-based, growth oriented, independent pharmaceutical company. StockPotentials reports cover smaller companies eResearch believes would be primarily of interest to retail investors.
RX.VN: 10.250 (+0.010)
eResearch Issues Stock Potentials Report on BioSyent Inc.
ACCESSWIRE - Thu Jul 03, 10:51AM CDT
Toronto, ON / ACCESSWIRE / July 3, 2014 / eResearch Corporation provides Stock Potentials reports to highlight interesting prospects which may benefit from the exposure that eResearch can provide through its extensive electronic distribution network. This latest report features BioSyent Inc., a growth-oriented specialty pharmaceutical company, based in Toronto.
RX.VN: 10.250 (+0.010)
BioSyent to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Marketwire - Fri Jun 13, 4:13PM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the 2014 Bloom Burton & Co. Healthcare Investor Conference at 4:30pm (ET), June 18, 2014 at the Toronto Board of Trade. Mr. Goehrum will provide an overview of the Company and its corporate activities.
RX.VN: 10.250 (+0.010)
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 year Revenue Growth Rate of 608%
Marketwire - Thu Jun 12, 3:02PM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that Canadian Business and PROFIT has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2014 rankings. Published in the July issue of Canadian Business and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2008-2013) growth rate of 608%, BioSyent ranked 104 on the PROFIT 500 list. This is the second consecutive year that BioSyent has been named to the Profit 500 list and marks a significant increase in 5 year growth rate, from 355% on last year's list to 608% on this year's list.
RX.VN: 10.250 (+0.010)
BioSyent Pharma Receives Health Canada Approval to Market New Urgent Care Product
Marketwire - Thu Jun 12, 7:03AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has received Health Canada - Therapeutics Products Directorate approval to market a new urgent care product. This is the first of two products that were in-licensed from a European partner and submitted to Health Canada in 2013 for approval.
RX.VN: 10.250 (+0.010)
Heavy Rains Threaten Household Food Security
by Tendayi Nyahuye and Farai Rugeje - All Africa Global Media - Fri Feb 14, 2:05AM CST
Heavy rains received this month have impacted negatively on the food security of households after destroying crops in most parts of the country. Floods have been experienced in low-lying areas like Chivi, Masvingo and Tsholotsho, but the worst hit is the Tokwe-Mukosi area where the water in the dam has risen to dangerous levels.
RX.VN: 10.250 (+0.010)
BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years
Marketwire - Thu Feb 13, 7:01AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) announced today that it has again been named as one of the TSX Venture Top 50 companies.
RX.VN: 10.250 (+0.010)
North American Palladium Reports Positive Production Ramp Up Progress
Marketwire Canada - Wed Feb 12, 4:03PM CST
All figures are in Canadian dollars except where noted.
PDL.TO: 0.16 (unch), PAL: 0.13 (unch), RX.VN: 10.250 (+0.010)
BioSyent Pharma Launches New Proktis-M(R) Suppositories
Marketwired - Mon Nov 24, 7:07AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M(R) suppositories. RX.VN: 10.250 (+0.010)
BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
Marketwired - Mon Oct 20, 7:06AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) released today a summary of its Third Quarter (Q3 2014) and nine months financial results for the three and nine months ending September 30, 2014. Key highlights include: RX.VN: 10.250 (+0.010)
BioSyent Releases Q2 and Six Month Results-Q2 Sales Increase 72%, Net Income After Tax Up 112%
Marketwire - Thu Aug 21, 7:03AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) released today a summary of its Second Quarter (Q2 2014) and first half (H1 2014) financial results for the three and six months ending June 30, 2014. Key highlights include: RX.VN: 10.250 (+0.010)
BioSyent Pharma Signs Exclusive Licensing and Distribution Agreement For New Urgent Care Drug Product
Marketwire - Wed Jul 23, 8:44AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and Distribution Agreement with an existing European partner for a new product that will be marketed by its' Hospital Products Division. The new product utilizes a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies. The product will be launched after Health Canada approval. RX.VN: 10.250 (+0.010)
BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com
Thomson Reuters ONE - Mon Jul 07, 6:28PM CDT
Vancouver, BC, July 7, 2014 - Toronto based eResearch has issued a StockPotentials report on BioSyent Inc. (TSXV:RX), a Toronto-based, growth oriented, independent pharmaceutical company. StockPotentials reports cover smaller companies eResearch believes would be primarily of interest to retail investors.
RX.VN: 10.250 (+0.010)
eResearch Issues Stock Potentials Report on BioSyent Inc.
ACCESSWIRE - Thu Jul 03, 10:51AM CDT
Toronto, ON / ACCESSWIRE / July 3, 2014 / eResearch Corporation provides Stock Potentials reports to highlight interesting prospects which may benefit from the exposure that eResearch can provide through its extensive electronic distribution network. This latest report features BioSyent Inc., a growth-oriented specialty pharmaceutical company, based in Toronto.
RX.VN: 10.250 (+0.010)
BioSyent to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Marketwire - Fri Jun 13, 4:13PM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the 2014 Bloom Burton & Co. Healthcare Investor Conference at 4:30pm (ET), June 18, 2014 at the Toronto Board of Trade. Mr. Goehrum will provide an overview of the Company and its corporate activities. RX.VN: 10.250 (+0.010)
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 year Revenue Growth Rate of 608%
Marketwire - Thu Jun 12, 3:02PM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) is pleased to announce that Canadian Business and PROFIT has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2014 rankings. Published in the July issue of Canadian Business and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2008-2013) growth rate of 608%, BioSyent ranked 104 on the PROFIT 500 list. This is the second consecutive year that BioSyent has been named to the Profit 500 list and marks a significant increase in 5 year growth rate, from 355% on last year's list to 608% on this year's list. RX.VN: 10.250 (+0.010)
BioSyent Pharma Receives Health Canada Approval to Market New Urgent Care Product
Marketwire - Thu Jun 12, 7:03AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has received Health Canada - Therapeutics Products Directorate approval to market a new urgent care product. This is the first of two products that were in-licensed from a European partner and submitted to Health Canada in 2013 for approval. RX.VN: 10.250 (+0.010)
Heavy Rains Threaten Household Food Security
by Tendayi Nyahuye and Farai Rugeje - All Africa Global Media - Fri Feb 14, 2:05AM CST
Heavy rains received this month have impacted negatively on the food security of households after destroying crops in most parts of the country. Floods have been experienced in low-lying areas like Chivi, Masvingo and Tsholotsho, but the worst hit is the Tokwe-Mukosi area where the water in the dam has risen to dangerous levels.
RX.VN: 10.250 (+0.010)
BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years
Marketwire - Thu Feb 13, 7:01AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) announced today that it has again been named as one of the TSX Venture Top 50 companies. RX.VN: 10.250 (+0.010)
North American Palladium Reports Positive Production Ramp Up Progress
Marketwire Canada - Wed Feb 12, 4:03PM CST
All figures are in Canadian dollars except where noted.
PDL.TO: 0.16 (unch), PAL: 0.13 (unch), RX.VN: 10.250 (+0.010)
